AstraZeneca PLC AstraZeneca appoints Iskra Reic EVP International

RNS Number : 8090O

AstraZeneca PLC

04 December 2024

 

 

4 December 2024

 

AstraZeneca appoints Iskra Reic as Executive Vice President, International

AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and driving sustainable growth across this broad region. This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.

Having joined the Company in 2001, Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa. She was appointed EVP for Europe & Canada in 2017 and joined AstraZeneca's Senior Executive Team. Most recently, Iskra launched the Company's Vaccines and Immune Therapies unit, successfully establishing it at the forefront of a new and exciting era of disease prevention. In this role, she was responsible for the early and late-stage development of the pipeline and portfolio, including COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations.

Pascal Soriot, CEO, said: "Iskra is a highly accomplished leader with extensive international experience across multiple disciplines and a track record of improving patient access to our innovative and life-changing medicines. Her experience building partnerships will be invaluable in taking the fast-growing International region forward."

Iskra Reic, Executive Vice President, International, said: "It is a privilege to lead this broad, diverse and innovative region as we deliver the next wave of science and innovative medicines. I look forward to working with our partners, stakeholders and colleagues to improve the lives of millions of people around the world with our leading medicines and vaccines."

Iskra succeeds Leon Wang who is on extended leave from the Company while under investigation in China.

Biography of Iskra Reic

Iskra Reic joined AstraZeneca in 2001 and has since held numerous leadership positions within the Company, including as Executive Vice-President (EVP) for Europe & Canada and, since 2021, as EVP, Vaccines & Immune Therapies. She has also held senior roles across Central & Eastern Europe, Eurasia, Middle East and Africa. Iskra has served on AstraZeneca's Senior Executive Team since 2017.

 

As EVP, Vaccines & Immune Therapies, Iskra was responsible for both the early and late-stage development of the Unit's pipeline and portfolio, including COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations.

 

Iskra has a PhD and an MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia. She also holds a DMD from the Medical University of Zagreb. She is a member of the Board of Directors of myTomorrows, a global health technology company, and Steering Committee of the Partnership for Health System Sustainability and Resilience, a global collaboration dedicated to improving patient outcomes.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAFZLFBZLLXFBK